MedImmune LLC, Clinical Pharmacology, Drug Metabolism, and Pharmacokinetics, Cambridge, UK.
CPT Pharmacometrics Syst Pharmacol. 2014 Feb 19;3(2):e101. doi: 10.1038/psp.2013.77.
Based on the author's recent experience, there appears to be some confusion regarding the steps required to qualify a systems pharmacology model as adequate for the intended purpose. This manuscript outlines the model evaluation approach used in the author's recent publication(1) on the systems pharmacology of a 5-lipoxygenase inhibitor and is an attempt to generate discussion on this topic within the pharmacometrics and systems pharmacology community.
基于作者最近的经验，似乎对于将系统药理学模型达到预期目的所需的步骤存在一些混淆。本文概述了作者最近在关于 5-脂氧合酶抑制剂的系统药理学研究(1)中使用的模型评估方法，并试图在药物代谢动力学和系统药理学领域内就该主题展开讨论。
